German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘Low Interventional ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the ...

Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...